Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2021
AGC Biologics wins 2021 Transatlantic Award
AGC Biologics won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy for its investments in the Italian biopharmaceutical industry. The award was presented at a gala dinner on December 2 in Milan.
2020
AGC Biologics expands Novavax partnership for U.S. adjuvant supply
AGC Biologics announced an expanded partnership with Novavax, adding production of the Matrix-M adjuvant for Novavax’s COVID-19 vaccine at AGC Biologics’ Seattle facility to support U.S. supply.
2020
AGC Biologics announces planned acquisition of MolMed
AGC Biologics announced that it planned to acquire most of the share capital of Molecular Medicine S.p.A. (MolMed) on July 31, 2020.
2020
AGC Biologics acquires Colorado manufacturing facility
AGC Biologics announced that it had acquired a commercial manufacturing facility in Boulder, Colorado, previously owned by AstraZeneca.
2020
AGC Biologics announces purchase of Colorado manufacturing facility
AGC Biologics announced the purchase of a commercial manufacturing facility in Boulder, Colorado, formerly owned by AstraZeneca. The facility is expected to begin full-scale operations and manufacturing by April 2021.
2020
AGC Biologics and AdaptVac announce vaccine-development partnership
AGC Biologics announced a partnership with AdaptVac to jointly develop and manufacture a COVID-19 vaccine.
2019
AGC Biologics announces Seattle and Copenhagen capacity expansions
AGC Inc. announced plans to add a 500-liter mammalian-cell bioreactor at AGC Biologics’ Seattle facility and install a purification line and additional analytic labs at its Copenhagen facility. Operations were scheduled to begin in April 2020 in the US and October in Europe.
2019
AGC Biologics appoints Copenhagen facility director/general manager
AGC Biologics announced the appointment of Jeffery D. Mowery as director/general manager of its Copenhagen facility.